Historical Valuation
BioXcel Therapeutics Inc (BTAI) is now in the Fair zone, suggesting that its current forward PS ratio of 27.88 is considered Fairly compared with the five-year average of -2.71. The fair price of BioXcel Therapeutics Inc (BTAI) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：2.01
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
BioXcel Therapeutics Inc (BTAI) has a current Price-to-Book (P/B) ratio of -0.38. Compared to its 3-year average P/B ratio of 3.87 , the current P/B ratio is approximately -109.88% higher. Relative to its 5-year average P/B ratio of 3.64, the current P/B ratio is about -110.49% higher. BioXcel Therapeutics Inc (BTAI) has a Forward Free Cash Flow (FCF) yield of approximately -156.58%. Compared to its 3-year average FCF yield of -276.33%, the current FCF yield is approximately -43.34% lower. Relative to its 5-year average FCF yield of -171.78% , the current FCF yield is about -8.85% lower.
P/B
Median3y
3.87
Median5y
3.64
FCF Yield
Median3y
-276.33
Median5y
-171.78
Competitors Valuation Multiple
AI Analysis for BTAI
The average P/S ratio for BTAI competitors is 4.71, providing a benchmark for relative valuation. BioXcel Therapeutics Inc Corp (BTAI.O) exhibits a P/S ratio of 27.88, which is 491.8% above the industry average. Given its robust revenue growth of -54.21%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for BTAI
1Y
3Y
5Y
Market capitalization of BTAI increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BTAI in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is BTAI currently overvalued or undervalued?
BioXcel Therapeutics Inc (BTAI) is now in the Fair zone, suggesting that its current forward PS ratio of 27.88 is considered Fairly compared with the five-year average of -2.71. The fair price of BioXcel Therapeutics Inc (BTAI) is between to according to relative valuation methord.
What is BioXcel Therapeutics Inc (BTAI) fair value?
BTAI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of BioXcel Therapeutics Inc (BTAI) is between to according to relative valuation methord.
How does BTAI's valuation metrics compare to the industry average?
The average P/S ratio for BTAI's competitors is 4.71, providing a benchmark for relative valuation. BioXcel Therapeutics Inc Corp (BTAI) exhibits a P/S ratio of 27.88, which is 491.80% above the industry average. Given its robust revenue growth of -54.21%, this premium appears unsustainable.
What is the current P/B ratio for BioXcel Therapeutics Inc (BTAI) as of Jan 10 2026?
As of Jan 10 2026, BioXcel Therapeutics Inc (BTAI) has a P/B ratio of -0.38. This indicates that the market values BTAI at -0.38 times its book value.
What is the current FCF Yield for BioXcel Therapeutics Inc (BTAI) as of Jan 10 2026?
As of Jan 10 2026, BioXcel Therapeutics Inc (BTAI) has a FCF Yield of -156.58%. This means that for every dollar of BioXcel Therapeutics Inc’s market capitalization, the company generates -156.58 cents in free cash flow.
What is the current Forward P/E ratio for BioXcel Therapeutics Inc (BTAI) as of Jan 10 2026?
As of Jan 10 2026, BioXcel Therapeutics Inc (BTAI) has a Forward P/E ratio of -0.41. This means the market is willing to pay $-0.41 for every dollar of BioXcel Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for BioXcel Therapeutics Inc (BTAI) as of Jan 10 2026?
As of Jan 10 2026, BioXcel Therapeutics Inc (BTAI) has a Forward P/S ratio of 27.88. This means the market is valuing BTAI at $27.88 for every dollar of expected revenue over the next 12 months.